XML 162 R32.htm IDEA: XBRL DOCUMENT v3.24.2

Related Parties Transactions (Tables)

3 Months Ended

12 Months Ended

Mar. 31, 2024

Dec. 31, 2023

Related Parties Transactions [Abstract]

Schedule of Related Parties of the Company with whom Transactions

The related parties of the Company with whom transactions are reported in these financial statements are as follows:

Name of entity or Individual		Relationship with the Company and its subsidiaries
BioFirst Corporation (the “BioFirst”)		Entity controlled by controlling beneficiary shareholder of YuanGene
BioFirst (Australia) Pty Ltd. (the “BioFirst (Australia)”)		100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene
Rgene Corporation (the “Rgene”)		Shareholder of the Company; Entity controlled by controlling beneficiary shareholder of YuanGene; the Chairman of Rgene is Mr. Tsung-Shann Jiang
YuanGene Corporation (the “YuanGene”)		Controlling beneficiary shareholder of the Company
AsiaGene Corporation (the “AsiaGene”)		Shareholder; entity controlled by controlling beneficiary shareholder of YuanGene
Keypoint Technology Ltd. (the “Keypoint’)		The Chairman of Keypoint is Eugene Jiang’s mother.
Lion Arts Promotion Inc. (the “Lion Arts”)		Shareholder of the Company
Yoshinobu Odaira (the “Odaira”)		Director of the Company
GenePharm Inc. (the “GenePharm”)		Dr. George Lee, Board Director of BioKey, is the Chairman of GenePharm.
Euro-Asia Investment & Finance Corp Ltd. (the “Euro-Asia”)		Shareholder of the Company
LBG USA, Inc. (the “LBG USA”)		100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene
LionGene Corporation (the “LionGene”)		Shareholder of the Company; Entity controlled by controlling beneficiary shareholder of YuanGene
Kimho Consultants Co., Ltd. (the “Kimho”)		Shareholder of the Company
The Jiangs		Mr. Tsung-Shann Jiang, the controlling beneficiary shareholder of the Company; the Chairman of Rgene; the Chairman and CEO of the BioLite Holding Inc. and BioLite Inc. and the President and a member of board of directors of BioFirst   Ms. Shu-Ling Jiang, Mr. Tsung-Shann Jiang’s wife, is the Chairman of Keypoint; and a member of board of directors of BioLite Inc.   Mr. Eugene Jiang is Mr. and Ms. Jiang’s son. Mr. Eugene Jiang is the chairman, and majority shareholder of the Company and a member of board of directors of BioLite Inc.   Mr. Chang-Jen Jiang is Mr. Tsung-Shann Jiang’s sibling and the director of the Company.   Ms. Mei-Ling Jiang is Ms. Shu-Ling Jiang’s sibling.
Zhewei Xu		Shareholder of the Company
BioHopeKing Corporation		Entity controlled by controlling beneficiary shareholder of ABVC
Jaimes Vargas Russman		CEO of AiBtl BioPharma Inc
Amkey Ventures, LLC (“Amkey”)		An entity controlled by Dr. George Lee, who serves as one of the board directors of BioKey, Inc
BioLite Japan		Entity controlled by controlling beneficiary shareholder of ABVC
BioHopeKing Corporation		Entity controlled by controlling beneficiary shareholder of ABVC
ABVC BioPharma (HK), Limited		An entity 100% owned by Mr. Tsung-Shann Jiang

The related parties of the company with whom transactions are reported in these financial statements are as follows:

Name of entity or Individual		Relationship with the Company and its subsidiaries
BioFirst Corporation (the “BioFirst”)		Entity controlled by controlling beneficiary shareholder of YuanGene
BioFirst (Australia) Pty Ltd. (the “BioFirst (Australia)”)		100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene
Rgene Corporation (the “Rgene”)		Shareholder of the Company; Entity controlled by controlling beneficiary shareholder of YuanGene; the Chairman of Rgene is Mr. Tsung-Shann Jiang
Eugene Jiang		Former President and Chairman
GenePharm Inc. (the “GenePharm”)		Dr. George Lee, Board Director of Biokey, is the Chairman of GenePharm.
The Jiangs		Mr. Tsung-Shann Jiang, the controlling beneficiary shareholder of the Company and Rgene, the Chairman and CEO of the BioLite Holding Inc. and BioLite Inc. and the President and a member of board of directors of BioFirst   Ms. Shu-Ling Jiang, Mr. Tsung-Shann Jiang’s wife, is the Chairman of Keypoint; and a member of board of directors of BioLite Inc.   Mr. Eugene Jiang is Mr. and Ms. Jiang’s son. Mr. Eugene Jiang is the chairman, and majority shareholder of the Company and a member of board of directors of BioLite Inc.   Mr. Chang-Jen Jiang is Mr. Tsung-Shann Jiang’s sibling and the director of the Company.   Ms. Mei-Ling Jiang is Ms. Shu-Ling Jiang’s sibling.
Zhewei Xu		Shareholder of the Company.
BioHopeKing Corporation		Entity controlled by controlling beneficiary shareholder of ABVC
Jaimes Vargas Russman		CEO of AiBtl BioPharma Inc.

Schedule of Accounts Receivable Due From Related Parties

Accounts receivable due from related parties consisted of the following as of the periods indicated:

		March 31,				December 31,
		2024				2023
		(Unaudited)
Rgene		$	10,463			$	10,463
Total		$	10,463			$	10,463

Accounts receivable due from related parties consisted of the following as of the periods indicated:

		December 31,				December 31,
		2023				2022
GenePharm Inc.		$	-			$	142,225
Rgene			10,463				615,118
Total		$	10,463			$	757,343

Schedule of Due From Related Parties - Current

Due from related–party - Current

		March 31,				December 31,
		2024				2023
		(Unaudited)
Rgene		$	541,372			$	541,486
BioFirst			346,565				206,087
Total		$	887,937			$	747,573

Due from related party - Current

		December 31,				December 31,
		2023				2022
Rgene		$	541,486			$	513,819
BioFirst			206,087				-
Total		$	747,573			$	513,819

Schedule of Due From Related Parties - Non Current

Due from related parties – Non-Current

		March 31,				December 31,
		2024				2023
BioFirst (Australia)		$	839,983			$	839,983
BioHopeKing Corporation			123,363				113,516
Total			963,346				953,499
Less: allowance for expected credit losses accounts			(839,983	)			(839,983	)
Net		$	123,363			$	113,516

Due from related parties- Non-current

		December 31,				December 31,
		2023				2022
BioFirst (Australia)		$	839,983				$ 752,655
BioHopeKing Corporation			113,516				112,822
Total			953,499				865,477
Less: allowance for expected credit losses accounts			(839,983	)			-
Net		$	113,516			$	865,477

Schedule of Amount Due to Related Parties

Amount due to related parties consisted of the following as of the periods indicated:

		March 31,				December 31,
		2024				2023
		(Unaudited)
The Jiangs		$	152,501			$	19,789
Due to shareholders			145,858				152,382
Due to a Director			3,613				961
Total		$	301,972			$	173,132

Amount due to related parties consisted of the following as of the periods indicated:

		December 31,				December 31,
		2023				2022
BioFirst		$	-			$	188,753
The Jiangs			19,789				19,789
Due to shareholders			152,382				151,450
Due to a Director			961				-
Total		$	173,132			$	359,992

Schedule of Revenue Due From Related Parties - Current

Revenue due from related parties consisted of the following as of the periods indicated:

		December 31,				December 31,
		2023				2022
Rgene		$	2,055			$	904,043
Total		$	2,055			$	904,043

X

- References

No definition available.

+ Details

Name:	abvc_ScheduleOfAccountReceivableDueFromRelatedPartiesTableTextBlock
Namespace Prefix:	abvc_
Data Type:	dtr:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of amount due to related parties.

+ References

No definition available.

+ Details

Name:	abvc_ScheduleOfAmountDueToRelatedPartiesTableTextBlock
Namespace Prefix:	abvc_
Data Type:	dtr:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Disclosure of due from related party.

+ References

No definition available.

+ Details

Name:	abvc_ScheduleOfDueFromRelatedPartyTableTextBlock
Namespace Prefix:	abvc_
Data Type:	dtr:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of information revenue due from related party.

+ References

No definition available.

+ Details

Name:	abvc_ScheduleOfRevenueDueFromRelatedPartyTextBlock
Namespace Prefix:	abvc_
Data Type:	dtr:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_RelatedPartyTransactionsAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details

Name:	us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.

+ References

No definition available.

+ Details

Name:	us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration